Change Condition: IBS-D
Overt HE  
Female nurse in glasses and white coat standing with arms crossed against an orange background.Female nurse in glasses and white coat standing with arms crossed against an orange background.

Clinical resources for
managing your adult
patients with irritable
bowel syndrome with
diarrhea (IBS-D)

Access experienced clinician perspectives,
tools, and educational material on
diagnosing and managing IBS-D, including
treatment with XIFAXAN® (rifaximin)

Resource Topics to Explore

Male physician in white lab coat sitting at desk holding pen and writing on a clipboard while talking to a patient. Male physician in white lab coat sitting at desk holding pen and writing on a clipboard while talking to a patient.

IBS-D Symptoms and Diagnosis

What causes IBS-D symptoms? How is IBS-D diagnosed? Watch your peers discuss how to make a positive IBS-D diagnosis and download useful resources to help your patients struggling with multiple symptoms.

Discover
Woman standing outdoors holding her stomach, representing abdominal discomfort. Woman standing outdoors holding her stomach, representing abdominal discomfort.

Managing IBS-D

How does IBS-D impact patients? What is recommended for patients struggling with multiple IBS-D symptoms? Watch patient case study videos and dive into clinical insights on best practices in managing patients with IBS-D.

Learn
Doctor discussing medical documents with a patient during an appointment in a bright office. Doctor discussing medical documents with a patient during an appointment in a bright office.

XIFAXAN® (rifaximin) FOR IBS-D

What does the clinical data say about XIFAXAN in patients with IBS-D? How do I implement XIFAXAN in my practice? Access resources about XIFAXAN safety and efficacy, XIFAXAN dosing, and tools to help ensure your patients get access to treatment.

Access

GastroHub Spotlight

Grey play button with square border.Video

8 mins

Recognizing the Symptoms of IBS-D

Featuring Kimberly Kearns, MS, APRN, ANP-BC

Follow along on the journey of Greg, a 29-year-old male who was referred to a gastroenterology specialist for frequent diarrhea accompanied by abdominal pain.

White download button on red background.Download Case Overview

DON’T MISS NEW RESOURCES

Sign up to stay informed of updates to GastroHub

Sign Up Now

 
Question mark inside a white thought bubble on a red background. Question mark inside a white thought bubble on a red background.

Have questions about IBS-D treatment with XIFAXAN? Request a rep.

A representative can schedule a time to visit your practice or assist you with ordering samples and accessing patient support materials.

Request a Rep
Calendar symbol inside of white thought bubble on red background. Calendar symbol inside of white thought bubble on red background.

Check for live and virtual conferences that may be relevant for your practice

Stay in the know and connect with your peers at upcoming live and virtual events.

See Events
See More

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • ​​XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
See Less

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • ​​XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
    –

    HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%)

    –

    IBS-D (≥2%): Nausea (3%), ALT increased (2%)

  • ​​INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

XIFI.0131.USA.24V2.0